| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
177,680,000 |
| Market
Cap: |
8.35(B) |
| Last
Volume: |
3,979,543 |
Avg
Vol: |
1,940,342 |
| 52
Week Range: |
$50.38 - $99.04 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 568 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Exact Sciences is a cancer screening and diagnostics company. Co.'s primary screening product, the Cologuard® test, is a non-invasive stool-based DNA screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Co.'s portfolio of Oncotype tests include: Oncotype DX gene expression tests for breast, prostate and colon cancers; Oncotype DX AR-V7 Nucleus Detect® test, a liquid-based test for advanced stage prostate cancer; and Oncotype MAP™ Pan-Cancer Tissue test (oncomap test), a test delivering tumor profiling to aid therapy selection for patients with metastatic, refractory or recurrent cancer.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
33,920 |
108,398 |
166,494 |
290,334 |
| Total Sell Value |
$2,062,221 |
$6,570,910 |
$11,277,891 |
$18,676,003 |
| Total People Sold |
10 |
10 |
11 |
11 |
| Total Sell Transactions |
20 |
52 |
61 |
100 |
| End Date |
2024-02-29 |
2023-11-28 |
2023-05-30 |
2022-05-30 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Condella Sarah |
EVP, Human Resources |
• – – |
2024-05-01 |
4 |
AS |
$60.15 |
$6,135 |
D/D |
(102) |
72,611 |
|
-17% |
|
| Cunningham Everett |
Chief Commercial Officer |
• – – |
2024-05-01 |
4 |
AS |
$60.15 |
$8,180 |
D/D |
(136) |
47,042 |
|
-17% |
|
| Elliott Jeffrey Thomas |
Chief Financial Officer |
• – – |
2024-05-01 |
4 |
AS |
$60.15 |
$8,180 |
D/D |
(136) |
11,795 |
|
-17% |
|
| Baranick Brian |
EVP, GM., Precision Oncology |
• – – |
2024-05-01 |
4 |
AS |
$60.15 |
$6,617 |
D/D |
(110) |
13,279 |
|
-17% |
|
| Orville Jacob A |
General Manager, Screening |
• – – |
2024-05-01 |
4 |
AS |
$60.15 |
$6,135 |
D/D |
(102) |
14,440 |
|
-17% |
|
| Conroy Kevin T |
President and CEO |
• • – |
2024-05-01 |
4 |
AS |
$60.15 |
$69,473 |
D/D |
(1,155) |
1,156,191 |
|
-17% |
|
| Coward D Scott |
|
– • – |
2024-05-01 |
4 |
AS |
$60.15 |
$4,030 |
D/D |
(67) |
44,644 |
|
-17% |
|
| Herriott James |
SVP, General Counsel & Sec |
• – – |
2024-05-01 |
4 |
AS |
$60.15 |
$1,805 |
D/D |
(30) |
9,866 |
|
-17% |
|
| Condella Sarah |
EVP, Human Resources |
• – – |
2024-04-30 |
4 |
A |
$0.00 |
$21,254 |
D/D |
926 |
72,713 |
|
- |
|
| Cunningham Everett |
Chief Commercial Officer |
• – – |
2024-04-30 |
4 |
A |
$0.00 |
$21,254 |
D/D |
999 |
47,178 |
|
- |
|
| Elliott Jeffrey Thomas |
Chief Financial Officer |
• – – |
2024-04-30 |
4 |
A |
$0.00 |
$21,224 |
D/D |
998 |
11,931 |
|
- |
|
| Baranick Brian |
EVP, GM., Precision Oncology |
• – – |
2024-04-30 |
4 |
A |
$0.00 |
$0 |
D/D |
218 |
13,389 |
|
- |
|
| Orville Jacob A |
General Manager, Screening |
• – – |
2024-04-30 |
4 |
A |
$0.00 |
$0 |
D/D |
218 |
14,542 |
|
- |
|
| Conroy Kevin T |
President and CEO |
• • – |
2024-04-30 |
4 |
A |
$0.00 |
$21,254 |
D/D |
3,197 |
1,157,346 |
|
- |
|
| Coward D Scott |
|
– • – |
2024-04-30 |
4 |
A |
$0.00 |
$0 |
D/D |
218 |
44,711 |
|
- |
|
| Herriott James |
SVP, General Counsel & Sec |
• – – |
2024-04-30 |
4 |
A |
$0.00 |
$21,254 |
D/D |
771 |
9,896 |
|
- |
|
| Baranick Brian |
EVP, GM., Precision Oncology |
• – – |
2024-04-02 |
4 |
AS |
$79.43 |
$73,393 |
D/D |
(924) |
13,171 |
|
-32% |
|
| Condella Sarah |
EVP, Human Resources |
• – – |
2024-04-01 |
4 |
AS |
$70.00 |
$140,000 |
D/D |
(2,000) |
71,787 |
|
-29% |
|
| Condella Sarah |
EVP, Human Resources |
• – – |
2024-03-28 |
4 |
AS |
$70.00 |
$140,000 |
D/D |
(2,000) |
73,787 |
|
-28% |
|
| Levangie Daniel J |
Director |
– • – |
2024-03-01 |
4 |
AS |
$57.50 |
$287,500 |
D/D |
(5,000) |
22,975 |
|
-16% |
|
| Conroy Kevin T |
President and CEO |
• • – |
2024-03-01 |
4 |
AS |
$59.32 |
$490,636 |
D/D |
(8,271) |
1,299,496 |
|
-16% |
|
| Condella Sarah |
EVP, Human Resources |
• – – |
2024-03-01 |
4 |
AS |
$59.32 |
$102,268 |
D/D |
(1,724) |
75,787 |
|
-16% |
|
| Elliott Jeffrey Thomas |
Chief Financial Officer |
• – – |
2024-03-01 |
4 |
AS |
$59.32 |
$143,080 |
D/D |
(2,412) |
10,933 |
|
-16% |
|
| Cunningham Everett |
Chief Commercial Officer |
• – – |
2024-03-01 |
4 |
AS |
$59.32 |
$143,080 |
D/D |
(2,412) |
46,179 |
|
-16% |
|
| Doyle James Edward |
Director |
– • – |
2024-03-01 |
4 |
AS |
$57.50 |
$115,000 |
D/D |
(2,000) |
50,110 |
|
-16% |
|
957 Records found
|
|
Page 1 of 39 |
|
|
2.82 (5.66%) 
